Munich (Germany) – December 7, 2011 – BICOLL announced today that it has entered into a sales agreement with CRELUX, a high quality protein and crystallography service provider. The two companies will jointly market their new platform technology to identify a broad range of small active bio-molecules for further (pre-)clinical development. CRELUX will base the establishment of new targets for its fragment based screening services on BICOLL’s unique proprietary small molecule natural product library BILOBAC N. BICOLL’s pooled and fractionated small molecule collections derive from endemic Asian plants that have a proven track record in the identification of new lead compounds. Some of which have already entered preclinical development status.
